Clinical trials: Invasive Carcinoma
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
This phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with stage I-III breast cancer after…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
- Trial name
- NCT06763328
- Testing
- Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- City of Hope Medical Center
Breast Cancer Female NOS, Tubular Breast Cancer Stage II
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.
- Conditions
- Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Invasive Ductal Breast Cancer
- Trial name
- GeparX (NCT02682693)
- Testing
- Denosumab, nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 780 people
- Sponsor
- GBG Forschungs GmbH
Non-muscle-invasive Bladder Cancer
Intravesical BCG vs GEMDOCE in NMIBC
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard…
- Trial name
- BRIDGE (NCT05538663)
- Testing
- Gemcitabine, Docetaxel, Bacillus Calmette Guerin
- Where
- 229 sites in United States
- Volunteers
- 870 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Bladder Cancer
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other…
- Trial name
- NCT06305767
- Testing
- Pembrolizumab, Intismeran autogene, Enfortumab Vedotin
- Where
- 74 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer Survivor, Ductal Breast Carcinoma In Situ
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
This phase II trial studies how well topical afimoxifene works in treating patients with breast cancer who have undergone radiation therapy on one breast.
- Conditions
- Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
- Trial name
- NCT04009044
- Testing
- Afimoxifene, Core Biopsy, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 156 people
- Sponsor
- Northwestern University
Endometrial Carcinoma
Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy)
Since the publication of the LAP2 study, a prospective randomized trial, laparoscopy has been considered the gold standard for treating patients with early-stage endometrial cancer (EC).
- Trial name
- LPSvsLPT (NCT06790004)
- Testing
- Laparotomy, Laparoscopy
- Where
- 8 sites in Italy
- Volunteers
- 700 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Bilateral Breast Carcinoma, HER2/Neu Negative
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
This phase II trial studies how well ixabepilone compared with standard of care works in treating patients with HER2/Neu negative breast cancer that remains after undergoing systemic therapy.
- Conditions
- Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
- Trial name
- NCT00877500
- Testing
- Best Practice, Ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Ductal Carcinoma in Situ
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of…
- Trial name
- DCIS (NCT05218044)
- Testing
- Cryoablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT03606967
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 30 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle…
- Trial name
- NCT05768347
- Testing
- Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual…
- Conditions
- Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- INSITE (NCT06396533)
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Fox Chase Cancer Center
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT00334815
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 61 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Robotic Radical Cystectomy Outcomes
Currently, in the treatment of bladder cancer the use of robotics has entered in clinical practice, therefor robotic radical cystectomy with or without reconstruction is offered to patients during counseling procedures, if deemed…
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Oncology, Recurrence
- Trial name
- NCT04900558
- Testing
- Radical Cystectomy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Florence
Non-Muscle- Invasive Bladder Cancer
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed…
- Trial name
- PATAPSCO (NCT05943106)
- Testing
- Durvalumab, BCG
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB…
- Trial name
- NCT06528847
- Testing
- Benmelstobart
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Invasive Breast Cancer
EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast
Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world.
- Trial name
- NCT05703815
- Volunteers
- 40 people
- Sponsor
- Sohag University
Muscle-invasive Urothelial Carcinoma of the Bladder
Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
This is a Phase 2, single-center, open-label, non-randomized study in patients with MIBC who cannot receive or refuse to receive cisplatin-based chemotherapy. Patients will be consecutively enrolled and treated.
- Trial name
- SURE-02 (NCT05535218)
- Testing
- Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Claudia Guerrieri
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01089088
- Testing
- cisplatin, gemcitabine hydrochloride, sunitinib malate
- Where
- 16 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Cardiff University
NMIBC
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) who are BCG Naïve or BCG Unresponsive and are considered ineligible for or have refused to undergo radical cystectomy, will receive RC48-ADC in…
- Trial name
- NCT05943379
- Testing
- RC48-ADC in Combination with gemcitabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RemeGen Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.